Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

SEC Filing – Royalty Pharma

S-1

February 2016 DC Beacon by The Beacon Newspapers - Issuu

Is WeWork bouncing back? Shared office space company reaches $228 million in revenue in September

Vertex touts Symdeko success in face of CEO turnover, Orkambi stumble

Amendment No. 1 to Draft Registration Statement

SEC Filing – Royalty Pharma

technologies for profiling single cells to create an open-access

SEC Filing – Royalty Pharma